{"nctId":"NCT00891176","briefTitle":"Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines","startDateStruct":{"date":"2009-05-14"},"conditions":["Neisseria Meningitidis","Haemophilus Influenzae Type b"],"count":582,"armGroups":[{"label":"Synflorix-Meningitec Group","type":"EXPERIMENTAL","interventionNames":["Biological: Pneumococcal conjugate vaccine GSK1024850A","Biological: MeningitecTM","Biological: InfanrixTM hexa","Biological: InfanrixTM IPV/Hib"]},{"label":"Synflorix-NeisVac-C Group","type":"EXPERIMENTAL","interventionNames":["Biological: Pneumococcal conjugate vaccine GSK1024850A","Biological: NeisVac-CTM","Biological: InfanrixTM hexa","Biological: InfanrixTM IPV/Hib"]},{"label":"Synflorix-Menitorix Group","type":"EXPERIMENTAL","interventionNames":["Biological: MenitorixTM","Biological: Pneumococcal conjugate vaccine GSK1024850A","Biological: InfanrixTM penta","Biological: InfanrixTM IPV"]},{"label":"Prevenar-Menitorix Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: MenitorixTM","Biological: Pneumococcal conjugate vaccine GSK1024850A","Biological: PrevenarTM","Biological: InfanrixTM penta","Biological: InfanrixTM IPV"]}],"interventions":[{"name":"MenitorixTM","otherNames":[]},{"name":"Pneumococcal conjugate vaccine GSK1024850A","otherNames":[]},{"name":"PrevenarTM","otherNames":[]},{"name":"MeningitecTM","otherNames":[]},{"name":"NeisVac-CTM","otherNames":[]},{"name":"InfanrixTM hexa","otherNames":[]},{"name":"InfanrixTM penta","otherNames":[]},{"name":"InfanrixTM IPV/Hib","otherNames":[]},{"name":"InfanrixTM IPV","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.\n* A male or female between, and including, 36 and 40 months of age at the time of Visit 1; between, and including, 48 and 52 months of age at the time of Visit 2; and between, and including, 72 and 76 months of age at the time of Visit 3.\n* Written informed consent obtained from the parent or guardian of the subject.\n* Healthy subjects as established by medical history and clinical examination before entering into the study.\n* Subjects who previously participated in the primary and booster studies, who received a full vaccination course with the vaccines corresponding to their group during the primary and booster studies and who were part, in the booster study, of the blood sampling subset.\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the first blood sampling.\n* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.\n* Administration of any additional meningococcal serogroup C, Hib, hepatitis B and pneumococcal vaccine since the end of the booster study\n* History of meningococcal serogroup C, Haemophilus influenzae type b, hepatitis B and invasive pneumococcal diseases since the end of booster study.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition since the end of booster study, based on medical history and physical examination (no laboratory testing required).\n* Administration of immunoglobulins and/or any blood products within the three months preceding the first blood sampling.","healthyVolunteers":true,"sex":"ALL","minimumAge":"36 Months","maximumAge":"76 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Titers Using Rabbit Complement (rSBA-MenC) Equal to or Above Cut-off Value","description":"rSBA-MenC antibody cut-off value assessed was equal to or above 1:8. The rSBA-MenC assay was performed at the Public Health England (PHE) laboratory at 6 years of age while the GSK laboratory was used for testing at 3 and 4 years of age.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null},{"groupId":"OG001","value":"144","spread":null},{"groupId":"OG002","value":"127","spread":null},{"groupId":"OG003","value":"113","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Titers Using Rabbit Complement (rSBA-MenC) Equal to or Above Cut-off Value","description":"rSBA-MenC antibody cut-off value assessed was equal to or above 1:8. The rSBA-MenC assay was performed at the Public Health England (PHE) laboratory at 6 years of age while the GSK laboratory was used for testing at 3 and 4 years of age.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"50","spread":null},{"groupId":"OG003","value":"34","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Titers Using Rabbit Complement (rSBA-MenC) Equal to or Above Cut-off Value","description":"rSBA-MenC antibody cut-off value assessed was equal to or above 1:8. The rSBA-MenC assay was performed at the Public Health England (PHE) laboratory at 6 years of age while the GSK laboratory was used for testing at 3 and 4 years of age.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"132","spread":null},{"groupId":"OG002","value":"108","spread":null},{"groupId":"OG003","value":"98","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With an rSBA-MenC Titer Equal to or Above Cut-off Value","description":"The cut-off value was defined as a titer equal to or above 1:128.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"109","spread":null},{"groupId":"OG002","value":"98","spread":null},{"groupId":"OG003","value":"68","spread":null}]}]}]},{"type":"SECONDARY","title":"rSBA-MenC Titers","description":"Titers are given as Geometric Mean Titers (GMTs).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.5","spread":null},{"groupId":"OG001","value":"235.3","spread":null},{"groupId":"OG002","value":"167.5","spread":null},{"groupId":"OG003","value":"84.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentrations Equal to or Above Cut-off Values","description":"The cut-off values were defined as a concentration equal to or above 0.15 microgram per milliliter (μg/mL) and equal to or above 1.0 μg/mL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"132","spread":null},{"groupId":"OG001","value":"139","spread":null},{"groupId":"OG002","value":"137","spread":null},{"groupId":"OG003","value":"138","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"101","spread":null},{"groupId":"OG001","value":"105","spread":null},{"groupId":"OG002","value":"127","spread":null},{"groupId":"OG003","value":"115","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PRP Concentrations","description":"Concentrations were defined as Geometric Mean Concentrations (GMCs) in μg/mL,","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.293","spread":null},{"groupId":"OG001","value":"2.222","spread":null},{"groupId":"OG002","value":"4.177","spread":null},{"groupId":"OG003","value":"3.636","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Concentrations Against Vaccine Pneumococcal Serotypes","description":"Antibody concentrations were expressed as GMCs in μg/mL.\n\nVaccine pneumococcal serotypes assessed included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.26","spread":null},{"groupId":"OG001","value":"0.23","spread":null},{"groupId":"OG002","value":"0.21","spread":null},{"groupId":"OG003","value":"0.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":null},{"groupId":"OG001","value":"0.23","spread":null},{"groupId":"OG002","value":"0.23","spread":null},{"groupId":"OG003","value":"0.35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.46","spread":null},{"groupId":"OG001","value":"0.39","spread":null},{"groupId":"OG002","value":"0.41","spread":null},{"groupId":"OG003","value":"0.09","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.59","spread":null},{"groupId":"OG001","value":"0.56","spread":null},{"groupId":"OG002","value":"0.63","spread":null},{"groupId":"OG003","value":"0.95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.58","spread":null},{"groupId":"OG001","value":"0.51","spread":null},{"groupId":"OG002","value":"0.54","spread":null},{"groupId":"OG003","value":"0.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":null},{"groupId":"OG001","value":"0.54","spread":null},{"groupId":"OG002","value":"0.47","spread":null},{"groupId":"OG003","value":"0.70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.33","spread":null},{"groupId":"OG001","value":"1.09","spread":null},{"groupId":"OG002","value":"1.00","spread":null},{"groupId":"OG003","value":"1.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":null},{"groupId":"OG001","value":"0.84","spread":null},{"groupId":"OG002","value":"0.59","spread":null},{"groupId":"OG003","value":"0.59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.06","spread":null},{"groupId":"OG001","value":"1.63","spread":null},{"groupId":"OG002","value":"1.35","spread":null},{"groupId":"OG003","value":"1.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.73","spread":null},{"groupId":"OG001","value":"0.69","spread":null},{"groupId":"OG002","value":"0.62","spread":null},{"groupId":"OG003","value":"1.36","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Opsonophagocytic Activity","description":"Opsonophagocytic activity was measured by a killing-assay. The results were presented as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The cut-off of the assay was an opsonic titre of 8.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"29","spread":null},{"groupId":"OG003","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"48","spread":null},{"groupId":"OG002","value":"43","spread":null},{"groupId":"OG003","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"47","spread":null},{"groupId":"OG002","value":"55","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"81","spread":null},{"groupId":"OG002","value":"78","spread":null},{"groupId":"OG003","value":"115","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":null},{"groupId":"OG001","value":"130","spread":null},{"groupId":"OG002","value":"131","spread":null},{"groupId":"OG003","value":"126","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null},{"groupId":"OG001","value":"131","spread":null},{"groupId":"OG002","value":"127","spread":null},{"groupId":"OG003","value":"124","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"118","spread":null},{"groupId":"OG002","value":"106","spread":null},{"groupId":"OG003","value":"112","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"44","spread":null},{"groupId":"OG003","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"108","spread":null},{"groupId":"OG002","value":"89","spread":null},{"groupId":"OG003","value":"91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"112","spread":null},{"groupId":"OG002","value":"113","spread":null},{"groupId":"OG003","value":"129","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentration of Antibodies Against Protein D","description":"Concentrations were expressed as GMCs in enzyme-linked immunosorbent-assay (ELISA) units per milliliter (EL.U/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"494.6","spread":null},{"groupId":"OG001","value":"444.8","spread":null},{"groupId":"OG002","value":"439.8","spread":null},{"groupId":"OG003","value":"100.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Equal to or Above Cut-off Values","description":"Cut-off values assessed were defined as equal to or above 10 milli-international units per milliliter (mIU/mL) or equal to or above 100 mIU/mL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"96","spread":null},{"groupId":"OG002","value":"102","spread":null},{"groupId":"OG003","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"81","spread":null},{"groupId":"OG002","value":"74","spread":null},{"groupId":"OG003","value":"74","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-HBs Antibody Concentrations","description":"Concentrations were expressed as GMCs in mIU/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"367.5","spread":null},{"groupId":"OG001","value":"325.7","spread":null},{"groupId":"OG002","value":"288.1","spread":null},{"groupId":"OG003","value":"371.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Related = SAE assessed by the investigator as being related to the study procedures.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"rSBA-MenC Titers","description":"Titers are given as Geometric Mean Titers (GMTs).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.3","spread":null},{"groupId":"OG001","value":"146.8","spread":null},{"groupId":"OG002","value":"112.4","spread":null},{"groupId":"OG003","value":"68.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With an rSBA-MenC Titer Equal to or Above Cut-off Value","description":"rSBA-MenC antibody cut-off value assessed was equal to or above 1:128.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"79","spread":null},{"groupId":"OG002","value":"75","spread":null},{"groupId":"OG003","value":"58","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentrations Equal to or Above Cut-off Values","description":"The cut-off values were defined as a concentration equal to or above 0.15 microgram per milliliter (μg/mL) and equal to or above 1.0 μg/mL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"133","spread":null},{"groupId":"OG001","value":"134","spread":null},{"groupId":"OG002","value":"130","spread":null},{"groupId":"OG003","value":"132","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"85","spread":null},{"groupId":"OG002","value":"117","spread":null},{"groupId":"OG003","value":"106","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PRP Concentrations","description":"Concentrations were defined as Geometric Mean Concentrations (GMCs) in μg/mL","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.767","spread":null},{"groupId":"OG001","value":"1.738","spread":null},{"groupId":"OG002","value":"3.804","spread":null},{"groupId":"OG003","value":"2.805","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Concentrations Against Vaccine Pneumococcal Serotypes","description":"Antibody concentrations were expressed as GMCs in μg/mL. Vaccine pneumococcal serotypes assessed included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":null},{"groupId":"OG001","value":"0.21","spread":null},{"groupId":"OG002","value":"0.18","spread":null},{"groupId":"OG003","value":"0.08","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":null},{"groupId":"OG001","value":"0.21","spread":null},{"groupId":"OG002","value":"0.20","spread":null},{"groupId":"OG003","value":"0.32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.47","spread":null},{"groupId":"OG001","value":"0.36","spread":null},{"groupId":"OG002","value":"0.34","spread":null},{"groupId":"OG003","value":"0.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.74","spread":null},{"groupId":"OG001","value":"0.65","spread":null},{"groupId":"OG002","value":"0.78","spread":null},{"groupId":"OG003","value":"0.99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.51","spread":null},{"groupId":"OG001","value":"0.44","spread":null},{"groupId":"OG002","value":"0.46","spread":null},{"groupId":"OG003","value":"0.09","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.52","spread":null},{"groupId":"OG001","value":"0.61","spread":null},{"groupId":"OG002","value":"0.54","spread":null},{"groupId":"OG003","value":"0.72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.51","spread":null},{"groupId":"OG001","value":"1.57","spread":null},{"groupId":"OG002","value":"1.41","spread":null},{"groupId":"OG003","value":"1.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.49","spread":null},{"groupId":"OG001","value":"0.81","spread":null},{"groupId":"OG002","value":"0.60","spread":null},{"groupId":"OG003","value":"0.49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.66","spread":null},{"groupId":"OG001","value":"2.36","spread":null},{"groupId":"OG002","value":"2.50","spread":null},{"groupId":"OG003","value":"2.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.98","spread":null},{"groupId":"OG001","value":"0.84","spread":null},{"groupId":"OG002","value":"0.98","spread":null},{"groupId":"OG003","value":"1.56","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Opsonophagocytic Activity","description":"Opsonophagocytic activity was measured by a killing-assay. The results were presented as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The cut-off of the assay was an opsonic titer of 8.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"20","spread":null},{"groupId":"OG003","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"50","spread":null},{"groupId":"OG002","value":"36","spread":null},{"groupId":"OG003","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"46","spread":null},{"groupId":"OG002","value":"40","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"101","spread":null},{"groupId":"OG003","value":"111","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"131","spread":null},{"groupId":"OG001","value":"134","spread":null},{"groupId":"OG002","value":"123","spread":null},{"groupId":"OG003","value":"126","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"125","spread":null},{"groupId":"OG001","value":"130","spread":null},{"groupId":"OG002","value":"118","spread":null},{"groupId":"OG003","value":"122","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"105","spread":null},{"groupId":"OG002","value":"95","spread":null},{"groupId":"OG003","value":"110","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"56","spread":null},{"groupId":"OG002","value":"46","spread":null},{"groupId":"OG003","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"88","spread":null},{"groupId":"OG002","value":"80","spread":null},{"groupId":"OG003","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"108","spread":null},{"groupId":"OG002","value":"86","spread":null},{"groupId":"OG003","value":"111","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentration of Antibodies Against Protein D","description":"Concentrations were expressed as GMCs in enzyme-linked immunosorbent-assay (ELISA) units per milliliter (EL.U/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"401.1","spread":null},{"groupId":"OG001","value":"387.2","spread":null},{"groupId":"OG002","value":"334.8","spread":null},{"groupId":"OG003","value":"107.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Equal to or Above Cut-off Values","description":"Cut-off values assessed were defined as equal to or above 10 milli-international units per milliliter (mIU/mL) or equal to or above 100 mIU/mL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"93","spread":null},{"groupId":"OG002","value":"86","spread":null},{"groupId":"OG003","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"62","spread":null},{"groupId":"OG003","value":"72","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-HBs Antibody Concentrations","description":"Concentrations were expressed as GMCs in mIU/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"273.5","spread":null},{"groupId":"OG001","value":"238.8","spread":null},{"groupId":"OG002","value":"174.6","spread":null},{"groupId":"OG003","value":"284.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Related = SAE assessed by the investigator as being related to the study procedures.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With rSBA-MenC Titer Equal to or Above Cut-off Value","description":"rSBA-MenC antibody cut-off value assessed was equal to or above 1:128.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"15","spread":null},{"groupId":"OG003","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"rSBA-MenC Titers","description":"Titers are given as Geometric Mean Titers (GMTs).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":null},{"groupId":"OG001","value":"11.9","spread":null},{"groupId":"OG002","value":"10.1","spread":null},{"groupId":"OG003","value":"8.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentrations Equal to or Above Cut-off Values","description":"The cut-off values were defined as a concentration ≥ 0.15 microgram per milliliter (μg/mL) and ≥ 1.0 μg/mL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":null},{"groupId":"OG001","value":"132","spread":null},{"groupId":"OG002","value":"130","spread":null},{"groupId":"OG003","value":"132","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"77","spread":null},{"groupId":"OG002","value":"110","spread":null},{"groupId":"OG003","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PRP Concentrations","description":"Concentrations were defined as Geometric Mean Concentrations (GMCs) in μg/mL","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.655","spread":null},{"groupId":"OG001","value":"1.647","spread":null},{"groupId":"OG002","value":"2.947","spread":null},{"groupId":"OG003","value":"2.558","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Concentrations Against Vaccine Pneumococcal Serotypes","description":"Antibody concentrations were expressed as GMCs in μg/mL. Vaccine pneumococcal serotypes assessed included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":null},{"groupId":"OG001","value":"0.22","spread":null},{"groupId":"OG002","value":"0.20","spread":null},{"groupId":"OG003","value":"0.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":null},{"groupId":"OG001","value":"0.14","spread":null},{"groupId":"OG002","value":"0.12","spread":null},{"groupId":"OG003","value":"0.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.37","spread":null},{"groupId":"OG001","value":"0.31","spread":null},{"groupId":"OG002","value":"0.30","spread":null},{"groupId":"OG003","value":"0.13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.71","spread":null},{"groupId":"OG001","value":"1.13","spread":null},{"groupId":"OG002","value":"1.28","spread":null},{"groupId":"OG003","value":"1.73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.61","spread":null},{"groupId":"OG001","value":"0.59","spread":null},{"groupId":"OG002","value":"0.64","spread":null},{"groupId":"OG003","value":"0.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":null},{"groupId":"OG001","value":"0.67","spread":null},{"groupId":"OG002","value":"0.57","spread":null},{"groupId":"OG003","value":"0.65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.84","spread":null},{"groupId":"OG001","value":"2.22","spread":null},{"groupId":"OG002","value":"2.81","spread":null},{"groupId":"OG003","value":"2.59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.52","spread":null},{"groupId":"OG001","value":"0.75","spread":null},{"groupId":"OG002","value":"0.56","spread":null},{"groupId":"OG003","value":"0.49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.91","spread":null},{"groupId":"OG001","value":"3.94","spread":null},{"groupId":"OG002","value":"4.24","spread":null},{"groupId":"OG003","value":"3.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.71","spread":null},{"groupId":"OG001","value":"1.70","spread":null},{"groupId":"OG002","value":"1.41","spread":null},{"groupId":"OG003","value":"2.99","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentration of Antibodies Against Protein D","description":"Concentrations were expressed as GMCs in enzyme-linked immunosorbent-assay (ELISA) units per milliliter (EL.U/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"284.7","spread":null},{"groupId":"OG001","value":"278.0","spread":null},{"groupId":"OG002","value":"266.1","spread":null},{"groupId":"OG003","value":"105.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Equal to or Above Cut-off Values as Measured by ELISA.","description":"Cut-off values assessed were defined as equal to or above 10 milli-international units per milliliter (mIU/mL) or equal to or above 100 mIU/mL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"92","spread":null},{"groupId":"OG002","value":"91","spread":null},{"groupId":"OG003","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"86","spread":null},{"groupId":"OG002","value":"79","spread":null},{"groupId":"OG003","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"79","spread":null},{"groupId":"OG002","value":"67","spread":null},{"groupId":"OG003","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"57","spread":null},{"groupId":"OG003","value":"67","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-HBs Antibody Concentrations as Measured by ELISA","description":"Concentrations were expressed as GMCs in mIU/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"433.8","spread":null},{"groupId":"OG001","value":"332.3","spread":null},{"groupId":"OG002","value":"302.7","spread":null},{"groupId":"OG003","value":"396.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"270.5","spread":null},{"groupId":"OG001","value":"263.1","spread":null},{"groupId":"OG002","value":"172.7","spread":null},{"groupId":"OG003","value":"280.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Equal to or Above Cut-off Values","description":"Cut-off values assessed were defined as equal to or above (≥) 6.2 milli-international units per milliliter (mIU/mL), 10 mIU/mL and 100 mIU/mL.\n\nNote: A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL) when tested by Enzyme-Linked Immunosorbent Assay (ELISA). The tables show both the results obtained by ELISA as well as updated results following complete retesting and reanalysis by a Chemiluminescence immunoassay (CLIA). Anti-HBs seroprotection was redefined as CLIA concentration above 10 mIU/mL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"121","spread":null},{"groupId":"OG002","value":"110","spread":null},{"groupId":"OG003","value":"113","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"113","spread":null},{"groupId":"OG002","value":"104","spread":null},{"groupId":"OG003","value":"109","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"108","spread":null},{"groupId":"OG002","value":"98","spread":null},{"groupId":"OG003","value":"112","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"118","spread":null},{"groupId":"OG002","value":"108","spread":null},{"groupId":"OG003","value":"111","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null},{"groupId":"OG001","value":"112","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"107","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"103","spread":null},{"groupId":"OG002","value":"91","spread":null},{"groupId":"OG003","value":"108","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"84","spread":null},{"groupId":"OG002","value":"75","spread":null},{"groupId":"OG003","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"76","spread":null},{"groupId":"OG002","value":"60","spread":null},{"groupId":"OG003","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"62","spread":null},{"groupId":"OG002","value":"45","spread":null},{"groupId":"OG003","value":"66","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-HBs Antibody Concentrations","description":"Concentrations were expressed as GMCs in mIU/mL. Note: A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL) when tested by ELISA. The tables show both the results obtained by ELISA as well as updated results following complete retesting and reanalysis by a Chemiluminescence immunoassay (CLIA).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"211.1","spread":null},{"groupId":"OG001","value":"189.2","spread":null},{"groupId":"OG002","value":"154.5","spread":null},{"groupId":"OG003","value":"218.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"130.8","spread":null},{"groupId":"OG001","value":"128.4","spread":null},{"groupId":"OG002","value":"92.3","spread":null},{"groupId":"OG003","value":"142.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"64.7","spread":null},{"groupId":"OG002","value":"45.7","spread":null},{"groupId":"OG003","value":"85.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Related = SAE assessed by the investigator as being related to the study procedures.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":144},"commonTop":[]}}}